Temozolomide in pediatric low-grade glioma

Pediatric Blood and Cancer

Volumn 49, Issue 6, 2007, Pages 808-811

  Khaw, Seong L ^a   Coleman, Lee T ^a   Downie, Peter A ^a,b   Heath, John A ^a   Ashley, David M ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

Low grade glioma; Pediatrics; Temozolomide

Indexed keywords

CARBOPLATIN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; TIOGUANINE; VINCRISTINE;

ADOLESCENT; ARTICLE; ASTROCYTOMA; BLOOD TOXICITY; CANCER GRADING; CANCER RADIOTHERAPY; CHILD; CLINICAL ARTICLE; CONSTIPATION; DATA ANALYSIS; DRUG TOLERABILITY; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROIMAGING; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; THROMBOCYTOPENIA;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC DISEASES; HUMANS; MALE; NAUSEA; RETROSPECTIVE STUDIES; SPINAL CORD NEOPLASMS; SURVIVAL RATE; VINCRISTINE;

EID: 34948862750     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21270     Document Type: Article

References (32)

1. Struther DR, Pollack IF, Fisher PG, et al. Tumours of the central nervous system. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams and Wilkins; 2002. pp 751-824.
2. Shaw EG, Wisoff JH. Prospective clinical trials of intracranial low-grade glioma in adults and children. Neurooncology 2003;5:153-160.
3. Fisher BJ, Leighton CC, Vujovic O, et al. Results of a policy of surveillance alone after surgical management of pediatric low-grade gliomas. Int J Radiat Oncol Biol Phys 2001;51:704-710.
4. Vera K, Djafari L, Faivre S, et al. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumours. Ann Oncol 2004;15:161-171.
5. Nagasubramanian R, Eileen Dolan M. Temozolomide: Realizing the promise and potential. Curr Opin Oncol 2003;15:412-418.
6. Van den Bent MJ, Hegi ME, Stupp R. Recent developments in the use of chemotherapy in brain tumours. Eur J Cancer 2006;42:582-588.
7. Gururangan S, Cavazos CM, Ashley D, et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol 2002;20:2951-2958.
8. Mahoney DH Jr, Cohen ME, Friedman HS, et al. Carboplatin is effective therapy for young children with progressive optic pathway tumours: A Pediatric Oncology Group phase II study. Neurooncology 2000;2:213-220.
9. Packer RJ, Ater J, Allen J, et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997;86:747-754.
10. Gnekow AK, Kortmann RD, Pietsch T, et al. Low-grade chiasmatic- hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy - report from the multicenter treatment study for children and adolescents with a low-grade glioma - HIT-LGG 1996 - of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr 2004;216:331-342.
11. Perilongo G. Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low-grade glioma. J Neurooncol 2005;75:301-307.
12. Massimino M, Spreafico F, Cefalo G, et al. High response rate to cisplatin, etoposide regimen in childhood low-grade glioma. J Clin Oncol 2002;20:4209-4216.
13. Prados MD, Edwards MSB, Rabbitt J, et al. Treatment of pediatric low-grade gliomas with a nitrosourea-based multiagent chemotherapy regimen. J Neurooncol 1997;32:235-241.
14. Laithier V, Grill J, Le Deley MC, et al. Progression-free survival in children with optic pathway tumors: Dependence of age and quality of response to chemotherapy - results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol 2003;21:4572-4578.
15. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005;352:987-996.
16. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
17. Maenpaa HO, Aaltonen K, Mantyla R. Temozolomide treatment in glioma. Acta Oncol 2004;43:579-584.
18. Newlands ES, Foster T, Zaknoen S. Phase I study of temozolomide combined with procarbazine in patients with gliomas. Br J Cancer 2003;89:248-251.
19. Van den Bent MJ, Keime-Guibert F, Brandes AA, et al. Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology 2001;57:340-342.
20. Brada M, Hoang-Xuan K, Rampling R, et al. Multicentre phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259-266.
21. Yung WKA, Prados MD, Yaya-Tur R, et al. Multicentre phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17:2762-2771.
22. Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J Clin Oncol 2001;19:2449-2455.
23. Lashford LS, Thiesse P, Jouvet A, et al. Temozolomide in malignant gliomas of childhood: A United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup study. J Clin Oncol 2002;20:4684-4691.
24. Broniscer A, Iacono L, Chintagumpala M, et al. Role of temozolomide after radiotherapy for newly diagnosed diffuse brainstem glioma in children. Cancer 2005;103:133-139.
25. Verschuur AC, Grill J, Lelouch-Tubiana A, et al. Temozolomide in paediatric high-grade glioma: A key for combination therapy? Br J Cancer 2004;91:425-429.
26. Van den Bent MJ, Taphoorn MJB, Brandes AA. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumours: The European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26971. J Clin Oncol 2003;21:2525-2528.
27. Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 2003;14:1715-1721.
28. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22:3133-3138.
29. Van den Bent MJ, Chinot O, Boogerd W, et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine, vincristine) chemotherapy: EORTC Brain Tumour Group phase II study 26972. Ann Oncol 2003;14:599-602.
30. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 2003;21:646-651.
31. Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response. Ann Oncol 2003;14:1722-1726.
32. Kuo DJ, Weiner HL, Wisoff J, et al. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol 2003;25:372-378.